Physician profile
Dawn M Ayers
NPI 1306823513
$46,739.38
in general payments reported to CMS, 2019-2025
60 companies · $2,030 in 2025
The $2,030 reported for 2025 was more than what 77% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $5,682 · 2021: $4,045 · 2022: $2,300 · 2023: $1,808 · 2024: $2,034 · 2025: $2,030.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,868 · Education: $4.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,867.53 |
| Education | $4.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $18,739.91 | 2019-2025 | Synthroid |
| Janssen Pharmaceuticals, INC | $14,468.08 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $2,830.57 | 2019-2025 | |
| Novo Nordisk INC | $1,352.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,130.19 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $898.00 | 2019-2024 | Farxiga |
| Amgen INC. | $857.71 | 2019-2025 | Tepezza, Repatha, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $642.27 | 2019-2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $502.81 | 2019-2025 | Strensiq |
| Bayer Healthcare Pharmaceuticals INC. | $496.71 | 2021-2025 | |
| Abbott Laboratories | $484.03 | 2019-2025 | Freestyle Libre 3, Eterna |
| Xeris Pharmaceuticals, INC. | $456.68 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Novartis Pharmaceuticals Corporation | $421.58 | 2022-2025 | |
| Corcept Therapeutics | $319.26 | 2019-2025 | Korlym |
| Mannkind Corporation | $288.18 | 2019-2025 |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $224.63 | 2023-2025 | Minimed 780g |
| Amneal Pharmaceuticals LLC | $217.77 | 2019-2025 | Unithroid |
| Horizon Therapeutics Plc | $209.03 | 2019-2023 | Tepezza |
| Tandem Diabetes Care, INC. | $176.46 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Currax Pharmaceuticals LLC | $174.80 | 2020-2025 | Contrave |
| Insulet Corporation | $128.21 | 2019-2025 | Omnipod |
| Merck Sharp & Dohme LLC | $120.98 | 2019-2023 | Steglatro |
| Antares Pharma, INC. | $103.70 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.83 | 2019-2024 | Cycloset |
| Esperion Therapeutics, INC. | $99.65 | 2023-2024 | Nexletol |
| Dexcom, INC. | $99.04 | 2019-2025 | Dexcom G6 Transmitter |
| Ibsa Pharma INC. | $95.91 | 2019-2025 | Tirosint, Flector, Licart |
| Recordati_rare_diseases_inc. | $94.33 | 2021-2024 | Isturisa |
| Grt US Holding, INC. | $88.95 | 2022 | |
| Astellas Pharma US INC | $77.92 | 2023-2025 | Veozah |
| Sequel Med Tech, LLC | $71.09 | 2025 | Twiist |
| Amryt Pharma Holdings Ltd | $67.53 | 2022-2023 | Mycapssa |
| Vivus LLC | $54.77 | 2019-2021 | |
| Beta Bionics, INC. | $52.18 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Cequr Corporation | $47.66 | 2023-2024 | Cequr Simplicity |
| Ultragenyx Pharmaceutical INC. | $47.22 | 2022-2024 | Crysvita |
| Nevro Corp. | $41.23 | 2022-2024 | Senza |
| Inspire Medical Systems, INC. | $39.58 | 2025 | Inspire |
| Medtronic Minimed, INC. | $39.03 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $39.02 | 2019 | |
| Neurocrine Biosciences, INC. | $31.71 | 2024-2025 | |
| Ascensia Diabetes Care US INC. | $27.09 | 2024 | |
| Soleno Therapeutics, INC. | $23.10 | 2025 | Vykat Xr |
| Pfizer INC. | $18.50 | 2019 | |
| Grifols USA, LLC | $18.02 | 2019 | |
| Radius Health, INC. | $17.15 | 2019 | |
| Amarin Pharma, INC. | $17.09 | 2019 | |
| Glaxosmithkline, LLC. | $17.05 | 2025 | Benlysta |
| Companion Medical, INC. | $16.54 | 2019 | |
| Halozyme INC | $16.24 | 2023 | |
| Ascendis Pharma Endocrinology INC | $15.82 | 2025 | Yorvipath |
| Zealand Pharma US, INC. | $15.28 | 2021 | |
| Eusa Pharma (US) LLC | $14.55 | 2022 | |
| Lifescan, INC. | $14.23 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $13.78 | 2020 | |
| Allergan, INC. | $13.13 | 2020 | |
| Acella Pharmaceuticals, LLC | $13.08 | 2021 | |
| Jazz Pharmaceuticals INC. | $12.38 | 2019 | |
| Valeritas, INC. | $12.34 | 2019 | |
| Shire North American Group INC | $12.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Ayers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.